<div class="white-sheet">
	<div class="content-slide">


		<div class="title-bar red"></div>

		<div class="wrapper slide-3-4-1">


			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
				<div data-effect="fade" data-duration="1000" data-target="information-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>
			</div>

			<div class="slide-title red two-line">
				Eltrombopag in severe aplastic anaemia: <br />indications for use
			</div>


			<div class="content-container">

				<ul>
					<li><span>Eltrombopag is indicated for the treatment of:</span>
						<ul>
							<li><span>Cytopenias in patients with SAA who have had an insufficient response to IST</span></li>
						</ul>
					</li>
					<li><span>Eltrombopag is also indicated for:</span>
						<ul>
							<li><span>Thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy</span></li>
							<li><span>Thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy</span></li>
						</ul>
					</li>
				</ul>

			</div>

		</div>


		<div class="information-overlay overlay">

			<header>Eltrombopag in severe aplastic anaemia: indications for use</header>
				
			<ul>
				<li><span>Limitations of use</span>
					<ul>
						<li><span>Eltrombopag should only be used in patients with: </span>
							<ul>
								<li><span>Immune thrombocytopenia whose degree of thrombocytopenia and clinical condition increase the risk for bleeding</span></li>
								<li><span>Chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon therapy or limits the ability to maintain optimal interferon-based therapy</span></li>
							</ul>
						</li>
						<li><span>Safety and efficacy have not been established in combination with direct-acting antiviral agents used without interferon for the treatment of chronic hepatitis C infection</span></li>
					</ul>
				</li>
			</ul>

		</div>


		<div class="references-overlay overlay">

			<header>References</header>
				
			<ul>
				<li class="navigateHref" data-navtarget="media/documents/module3/Promacta-PI-2014.pdf"><span>GlaxoSmithKline. Promacta (eltrombopag) tablets for oral use. Prescribing Information (draft). 2014</span></li>
			</ul>

		</div>
		

	</div>
</div>